Please fill the required information
OK

Please do not close or Refresh

Practice Information

Primary Practice Contact

Your practice’s main point of contact for Notal Vision
Please enter Numbers Only
* Indicates a required field

Office Information

Please enter Numbers Only
Please enter Numbers Only
Please enter Numbers Only

Primary Office Contact

Your office’s main point of contact for Notal Vision
Please enter Numbers Only

Patient Alert Recipients

Patient Alert notifications inform you of a statistically significant change in a patient’s test. It is also your office’s prompt to contact the patient for a follow up visit and to log into the ForeseeHome Prescriber Portal or App to review the patient’s report. A monthly summary report for each patient will also be sent to each email address listed. Please list up to three recipients below (at least one is required).

Check here if the Office Contact should receive Patient Alert Notifications.
Please enter Numbers Only
Please add the Recipient Div
Please add the Recipient Div
Add Additional Alert Recipients
Add Additional Offices
* Indicates a required field

FORESEEHOME PRESCRIBERS

List all eye care professionals authorized to prescribe ForeseeHome.

Prescriber Details

Prescriber Details

Prescriber Details 1

Please enter Numbers Only
Please enter Numbers Only
Add Additional Prescribers
* Indicates a required field

Patient Alert Communication

Enter Correct Captcha Code
refresh
* Indicates a required field

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.